Speakers

Expand/Collapse

Costas Lyssiotis
Associate Professor, Departments of Physiology and Medicine University of Michigan
University of Michigan

Nicholas Goldner
Chief Executive Officer, Co-Founder
ResistanceBio

Mallika Singh
Vice President, Translational Research
Revolution Medicine

Day One

Wednesday, February 23rd 2022

1:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

9:00 am | Mutant-Selective Inhibitors of RAS(ON) Beyond KRASG12C

Jack Sadowsky
Principal Investigator of Discovery Chemistry
Carmot Therapeutics

Day Two

Thursday, 24th February 2022

10:00 am | Chemotype Evolution Platform for Discovering Covalent Inhibitors of KRAS G12C & Beyond

Jeffrey Rothman
Assistant Professor
Columbia University Medical Center & CSO, Founder Oncogenuity

Day One

Wednesday, February 23rd 2022

1:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

10:00 am | Rationale for Complementary Targeting & Peptide Nucleic Acid Oligonucleotide Delivery for Allele-Specific Targeting of KRAS G12D

Iris Valtingojer
Group Leader, Oncology Research
Sanofi R&D

Day Two

Thursday, 24th February 2022

2:15 pm | MAPK & Hippo-YAP1 Signaling: At the Crossroads of Cancer Progression & Resistance to Therapy

Hanna Budayeva
Principal Scientific Researcher
Genentech

Day One

Wednesday, February 23rd 2022

3:15 pm | Increasing the Throughput of Ligandable Cysteine Hotspots Profiling by Mass Spectrometry to Guide RAS Pathway Drug Discovery

Reagan Jarvis
Chief Executive Officer
Anocca

Day Two

Thursday, 24th February 2022

9:00 am | T-Cell Receptor Targeting of Multiple RAS Mutant Forms in Broad Patient Populations

Andrea Gohlke
Senior Biophysics Scientist
AstraZeneca

Armon Sharei
CEO & Founder
SQZ Biotechnologies

Day Two

Thursday, 24th February 2022

9:30 am | 2nd Generation Antigen Presenting Cells for Multiple KRAS Mutations

Carmine Fedele
Principal Scientist II, Oncology-Drug Discovery
Novartis Institute of Biomedical Research

Marcel Frenkel
Chief Executive Officer
Ten63 Therapeutics

Jeff Ecsedy
Chief Scientific Officer
Ikena Oncology

Day One

Wednesday, February 23rd 2022

1:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

12:00 pm | Overcoming Therapeutic Resistance by Targeting Mutant-KRAS Transducers

Thomas Tibbitts
Chief Executive Officer
Dogodan Therapeutics

Day One

Wednesday, February 23rd 2022

3:45 pm | Developing Genomic Medicines for KRAS-Driven Cancers

Poulikos Poulikakos
Associate Professor
Icahn School of Medicine at Mount Sinai

Day One

Wednesday, February 23rd 2022

11:30 am | Targeting Adaptive Resistance to RAS/MAPK-Directed Therapies

Frantz Jean- Francois
Team Lead
RAS initiative Frederick National Laboratory for Cancer Research

Day Two

Thursday, 24th February 2022

11:30 am | PROTAC Mediated Degradation of KRAS

Michael Eck
Professor
Department of Biological Chemistry & Molecular Pharmacology Harvard Medical School

Day Two

Thursday, 24th February 2022

1:45 pm | Structural Insights into Pharmacologic Targeting of the RAS/ RAF/MEK/ERK Pathway

Raghu Kalluri
Professor & Chair
Department of Cancer Biology The University of Texas MD Anderson Cancer Center

Day One

Wednesday, February 23rd 2022

9:30 am | Targeting Oncogenic KRAS-G12D Mutation Employing Engineered Exosomes in Pancreatic Cancer

Siyuan Le
Senior Director of Biology
GenFleet Therapeutics

Day One

Wednesday, February 23rd 2022

1:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

Day Two

Thursday, 24th February 2022

2:45 pm | GFH925 (aka IBI351), A Novel Covalent Inhibitor for KRAS G12C

Greg Jones
Senior
Scientist & Team Leader Pfizer

Day One

Wednesday, February 23rd 2022

4:15 pm | Multi-Omics Data Integration Reveals Emerging Targets for RAS Mutant Cancers

1:30 pm | Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers

Sreesha Srinivasa
Chief Development Officer
Oblique Therapeutics

Day Two

Thursday, 24th February 2022

12:00 pm | Targeting KRAS with Mutant Selective Monoclonal Antibodies

Mark Hallen
Chief Technology Officer
Ten63 Therapeutics

Helen Mott
Associate Professor
University of Cambridge

Erik Knelson
Medical Oncologist
Dana-Farber Cancer Institute

Trever Bivona
Professor, Hematology & Oncology
UCSF